Next Article in Journal
Underlying Mechanisms of Bergenia spp. to Treat Hepatocellular Carcinoma Using an Integrated Network Pharmacology and Molecular Docking Approach
Previous Article in Journal
Regulation of Adipose-Derived Stem Cell Activity by Melatonin Receptors in Terms of Viability and Osteogenic Differentiation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 16
Issue 9
10.3390/ph16091238
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Ginsenoside Rb1 Reduces Hyper-Vasoconstriction Induced by High Glucose and Endothelial Dysfunction in Rat Aorta

by
Jubin Park
1,2,†,
You Kyoung Shin
1,†,
Uihwan Kim
1,2 and
Geun Hee Seol
1,2,*
1
Department of Basic Nursing Science, College of Nursing, Korea University, Seoul 02841, Republic of Korea
2
BK21 FOUR Program of Transdisciplinary Major in Learning Health Systems, Graduate School, Korea University, Seoul 02841, Republic of Korea
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work and share first authorship.
Pharmaceuticals 2023, 16(9), 1238; https://doi.org/10.3390/ph16091238
Submission received: 1 August 2023 / Revised: 31 August 2023 / Accepted: 31 August 2023 / Published: 1 September 2023
(This article belongs to the Section Natural Products)
Browse Figures
Review Reports Versions Notes

Abstract

:
Acute hyperglycemia induces oxidative damage and inflammation, leading to vascular dysfunction. Ginsenoside Rb1 (Rb1) is a major component of red ginseng with anti-diabetic, anti-oxidant and anti-inflammatory properties. Here, we investigated the beneficial effects and the underlying mechanisms of Rb1 on hypercontraction induced by high glucose (HG) and endothelial dysfunction (ED). The isometric tension of aortic rings was measured by myography. The rings were treated with NG-nitro-L-arginine methyl ester (L-NAME) to induce chemical destruction of the endothelium, and Rb1 was added after HG induction. The agonist-induced vasoconstriction was significantly higher in the aortic rings treated with L-NAME + HG50 than in those treated with HG50 or L-NAME (p = 0.011) alone. Rb1 significantly reduced the hypercontraction in the aortic rings treated with L-NAME + HG50 (p = 0.004). The ATP-sensitive K+ channel (KATP) blocker glibenclamide tended to increase the Rb1-associated reduction in the agonist-induced vasoconstriction in the rings treated with L-NAME + HG50. The effect of Rb1 in the aortic rings treated with L-NAME + HG50 resulted from a decrease in extracellular Ca2+ influx through the receptor-operated Ca2+ channel (ROCC, 10−6–10−4 M CaCl2, p < 0.001; 10−3–2.5 × 10−3 M CaCl2, p = 0.001) and the voltage-gated Ca2+ channel (VGCC, 10−6 M CaCl2, p = 0.003; 10−5–10−2 M CaCl2, p < 0.001), whereas Rb1 did not interfere with Ca2+ release from the sarcoplasmic reticulum. In conclusion, we found that Rb1 reduced hyper-vasoconstriction induced by HG and ED by inhibiting the ROCC and the VGCC, and possibly by activating the KATP in rat aorta. This study provides further evidence that Rb1 could be developed as a therapeutic target for ED in diabetes.

1. Introduction

Pathological conditions can result in acute hyperglycemia. For example, acute pancreatitis can not only impair glucose metabolism [1] but can also induce endothelial injury and dysregulation of vasomotor tone due to inflammatory reactions [2]. High glucose (HG) concentrations have been reported to increase osteogenic protein activity in vascular smooth muscle cells in the presence of elastin-derived peptides and transforming growth factor-beta 1, which can lead to vascular calcifications [3]. In addition, HG was found to significantly increase lysine acetylation and the formation of reactive oxygen species (ROS) in vascular smooth muscle cells, processes that may be associated with impaired vascular smooth muscle cell-dependent vasorelaxation in a murine model of type 2 diabetes mellitus [4]. Hyperglycemia is a major factor in the development of endothelial dysfunction (ED) through oxidative stress and dysregulation of endothelial nitric oxide synthase [5]. A clinical study showed that acute glucose ingestion can increase oxidative stress, possibly degrading vascular endothelial function, even in healthy young men [6]. Blood sugar control alone did not effectively prevent cardiovascular complications in patients with type 2 diabetes and hyperglycemia [7]. Consequently, in patients with acute hyperglycemia, efforts should be made to prevent and treat abnormally increased vascular tone under conditions of ED.
Red ginseng (Ginseng Radix Rubra), a plant belonging to the family Araliaceae [8], has been used in traditional Korean medicine due to the pharmacological effects of the ginsenoside saponins contained in its roots, such as anti-oxidant, anti-inflammatory, and anti-diabetic properties [9]. It has been reported that there are several types of ginsenosides in red ginseng [10]. Ginsenosides can be divided into protopanaxadiol-type compounds, including Rb1, Rb2, Rc, and Rd, and protopanaxatriol-type compounds, including Rg1, Rg2, and Rh1, with both of these types possessing a dammarane triterpenoid structure [11]. The ginsenosides Rb1 (hereinafter, Rb1) and Rg1 (hereinafter, Rg1) used in the present study are representative components of protopanaxadiol-type and protopanaxatriol-type, respectively [12]. The chemical structures of Rb1 and Rg1 differ in aspects such as the positions of sugar moieties [13]. Both Rb1 and Rg1 are known to have antidiabetic effects [14,15]. Especially, Rb1 accounts for the largest proportion of ginsenoside saponins contained in red ginseng [10,16]. Rb1 was shown to stimulate the production of nitric oxide in vascular endothelial cells [17]. Rb1 was also found to down-regulate the Wnt/β-catenin pathway, which is associated with vascular calcification in rat vascular smooth muscle cells [18]. In pulmonary arteries, Rb1 was reported to inhibit store-operated Ca2+ entry (SOCE) by suppressing stromal interaction molecule activation rather than by altering Ca2+ release from the sarcoplasmic reticulum (SR), and thereby to decrease endothelin-1-induced vasoconstriction [19]. Furthermore, daily intraperitoneal injection of Rb1 for three weeks was reported to decrease SOCE and vasoconstriction in the pulmonary arteries of rats with pulmonary hypertension [20]. However, the effects of Rb1 on vasoconstriction under hyperglycemia and ED conditions remained unclear. Therefore, in the present study, we investigated the effects of Rb1 on hyper-vasoconstriction induced by HG and ED in rat aorta, and its underlying mechanisms.

2. Results

2.1. Effects of HG on Vasoconstriction in Rat Aorta

Analyses of the effects of HG on the agonist-induced vasoconstriction of aortic rings showed that HG concentrations of 25 mM (HG25) or 50 mM (HG50) did not significantly affect the agonist-induced vasoconstriction of rings with intact endothelium (Control, 1.08 ± 0.04 g; HG25, 1.05 ± 0.08 g; HG50, 1.13 ± 0.08 g). Also, there was no significant difference in the agonist-induced vasoconstriction between the rings treated with NG-nitro-L-arginine methyl ester (L-NAME, 1.10 ± 0.06 g) and L-NAME + HG25 (1.18 ± 0.06 g). In contrast, the agonist-induced vasoconstriction was significantly higher in the rings treated with L-NAME + HG50 (1.32 ± 0.06 g) than in the control (p = 0.007) and L-NAME-treated (p = 0.011) rings. The agonist-induced vasoconstriction of aortic rings was not significantly different between the L-NAME + Mannitol (1.22 ± 0.03 g) group and the control group. These results suggest that vasoconstriction was significantly increased only after simultaneous treatment with HG50 and L-NAME for denudation of the endothelium, and thus was attributable to the HG condition rather than a hyperosmotic effect (Figure 1A).

2.2. Effects of Rb1 on Hyper-Vasoconstriction Induced by HG and ED in Rat Aorta

The effects of 10−6 or 10−5 M Rb1 (called Rb1 1 and Rb1 10, respectively) or Rg1 (called Rg1 1 or Rg1 10, respectively), or 10−5 M N-acetylcysteine (NAC 10) on hyper-vasoconstriction induced by HG and ED were evaluated. The agonist-induced vasoconstriction in the aortic rings treated with L-NAME + Rb1 1 (1.09 ± 0.04 g), L-NAME + Rb1 10 (1.11 ± 0.05 g), and L-NAME + Rg1 10 (1.14 ± 0.05 g) did not differ significantly from the agonist-induced vasoconstriction in the rings treated with L-NAME alone (1.10 ± 0.06 g). Similarly, the agonist-induced vasoconstriction in the aortic rings treated with L-NAME + HG25 + Rb1 1 (1.18 ± 0.04 g), L-NAME + HG25 + Rb1 10 (1.11 ± 0.05 g), and L-NAME + HG25 + Rg1 10 (1.19 ± 0.04 g) did not differ significantly from the agonist-induced vasoconstriction in the aortic rings treated with L-NAME + HG25 (1.18 ± 0.06 g). Compared to the aortic rings treated with L-NAME + HG50 (1.32 ± 0.06 g), the agonist-induced vasoconstriction in the rings treated with L-NAME + HG50 + Rb1 10 (1.11 ± 0.04 g, p = 0.004) was significantly reduced to a level similar to that seen in the L-NAME + HG50 + NAC 10 (1.14 ± 0.06 g) group; however, such a reduction was not seen in the rings treated with L-NAME + HG50 + Rg1 10 (1.28 ± 0.05 g) (Figure 1B).

2.3. Effect of K+ Channel Blockers on Rb1-Treated Hyper-Vasoconstriction Induced by HG and ED in Rat Aorta

To assess the mechanism underlying the effect of Rb1 10 on agonist-induced vasoconstriction, aortic rings were treated with several K+ channel blockers. Tetraethylamine (TEA, 1.09 ± 0.04 g), barium chloride (BaCl2, 1.11 ± 0.03 g), and 4-aminopyridine (4-AP, 1.09 ± 0.04 g) did not significantly alter the agonist-induced vasoconstriction in the aortic rings treated with L-NAME + HG50 + Rb1 10 (1.11 ± 0.05 g), whereas the agonist-induced vasoconstriction tended to be higher in the rings treated with L-NAME + HG50 + Rb1 10 + Glibenclamide (Gliben, 1.21 ± 0.03 g) than with L-NAME + HG50 + Rb1 10 (1.11 ± 0.05 g; p = 0.062). These results suggested that activation of the ATP-sensitive K+ channel (KATP) may be involved in the inhibitory effect of Rb1 on hyper-vasoconstriction induced by HG and ED (Figure 2A).

2.4. Effect of SR Ca2+ Release and Extracellular Ca2+ Influx on Rb1-Treated Hyper-Vasoconstriction Induced by HG and ED in Rat Aorta

To further explore the mechanism of the action of Rb1, its effects on vasoconstriction induced by SR Ca2+ release and extracellular Ca2+ influx were analyzed. Rb1 10 did not significantly affect vasoconstriction due to SR Ca2+ release, as shown by comparing the aortic rings treated with L-NAME + HG50 (0.30 ± 0.02 g) and L-NAME + HG50 + Rb1 10 (0.32 ± 0.02 g) (Figure 2B). In contrast, Rb1 10 significantly reduced vasoconstriction due to extracellular Ca2+ influx via the receptor-operated Ca2+ channel (ROCC, 10−6–10−4 M, p < 0.001; 10−3–2.5 × 10−3 M, p = 0.001) (Figure 2C) and the voltage-gated Ca2+ channel (VGCC, 10−6 M, p = 0.003; 10−5–10−2 M, p < 0.001) (Figure 2D).

3. Discussion

The present study found that the agonist-induced vasoconstriction of aortic rings with intact endothelium was not affected by the HG concentration. In the presence of ED, however, the agonist-induced vasoconstriction was significantly increased by the addition of 50 mM glucose. This concentration is relevant to that seen in the hyperosmolar hyperglycemic state [21] leading to acute pancreatitis [22]. This effect was independent of vascular contracting factors from the endothelium, such as endothelin-1 [23], indicating that HG has a direct effect on vascular smooth muscle cells. Furthermore, a mannitol-based hyperosmotic control did not show a vasoconstriction increase comparable to that seen in the HG50 group, suggesting that the HG was responsible for enhancing the agonist-induced vasoconstriction of vascular smooth muscle cells. The hyperpolarization of mitochondria in mouse vascular smooth muscle cells treated with HG was found to inhibit myosin light chain phosphatase, resulting in vascular smooth muscle contraction [24]. The exposure of murine aortic vascular smooth muscle cells to 30 mM glucose for 48 h was found to increase intracellular Ca2+ levels through SOCE [25]. Because acute pancreatitis is frequently accompanied by ED [2] and hyperglycemia [26], intracellular Ca2+ concentrations may be increased in the vascular smooth muscle cells of patients with acute pancreatitis, resulting in vascular hypercontraction.
The ability of Rb1 and Rg1 to reduce hyper-vasoconstriction induced by HG and ED was also evaluated. Although neither Rb1 nor Rg1 altered vasoconstriction in the aortic rings treated with L-NAME and L-NAME+HG25, Rb1 significantly reduced hyper-vasoconstriction induced by 50 mM glucose and ED, whereas Rg1 was ineffective. Rb1 was more effective than Rg1 in mitigating vascular smooth muscle dysfunction in the presence of angiotensin 2-induced abdominal aortic aneurysm [27] and inhibiting vascular inflammatory action in the coronary artery endothelium [28]. These different effects of Rb1 and Rg1 may reflect differences in their chemical configurations, such as the positions of sugar moieties and aglycone structures [13].
The effects of Rb1 on hyper-vasoconstriction induced by HG and ED were not altered by the K+ channel inhibitors, TEA, BaCl2, and 4-AP. In contrast, the KATP blocker Gliben tended to suppress the Rb1 inhibition of hyper-vasoconstriction induced by HG and ED. HG has been found to inhibit KATP activity in vascular smooth muscle, an inhibition mediated by increased superoxide production in the human omental artery [29]. Furthermore, the KATP is inhibited when intracellular ATP is decreased, followed by the opening of the VGCC, resulting in increased cytosolic Ca2+ levels [30,31]. Thus, Rb1 may inhibit extracellular Ca2+ influx through the activation of the KATP, thereby reducing hyper-vasoconstriction induced by HG and ED.
Rb1 has been found to reduce intracellular Ca2+ concentrations in the myocardial H9C2 cell hypoxia model, through a mechanism involving the downregulation of the calcium/calmodulin-dependent protein kinase II and the ryanodine receptor 2 [32]. Furthermore, Rb1 selectively suppressed the L-type VGCC in cultured rat hippocampus neurons [33]. To determine whether the effects of Rb1 on hyper-vasoconstriction induced by HG and ED were associated with Ca2+ flow, the effects of Rb1 on vasoconstriction induced by sarcoplasmic SR Ca2+ release or extracellular Ca2+ influx were measured. The ability of Rb1 to ameliorate the increased vasoconstriction induced by treatment with L-NAME and 50 mM glucose was found to be independent of SR Ca2+ release. In contrast, Rb1 was found to reduce hyper-vasoconstriction induced by HG and ED through inhibiting extracellular Ca2+ influx via the ROCC and the VGCC, regarded as the main Ca2+ channels for controlling vascular tension in vascular smooth muscle [34,35].
Pretreatment with Rb1 was found to inhibit Ca2+ increase through SOCE in pulmonary arterial smooth muscle cells [20]. Moreover, Rb1 significantly inhibited Ca2+ influx through SOCE only in vascular smooth muscle cells, but not in vascular endothelial cells, exposed to 30 mM glucose for 48 h [25]. In agreement with these findings, the present study found that Rb1 did not affect the agonist-induced vasoconstriction in aortas with HG and intact endothelium. This lack of effect may be due to endothelium-derived contracting factors, including angiotensin II [36], thromboxane [37], and endothelin-1 [38], released by HG stimulation.
Rb1 is expected to have therapeutic potential in diseases accompanied by hyperglycemia and ED. The present study indicates that Rb1, which possesses anti-diabetic properties [39], reduced hyper-vasoconstriction induced by HG and ED through the ROCC- and VGCC-mediated inhibition of extracellular Ca2+ influx and/or possibly through the KATP channel activation.
These findings indicate the importance of maintaining healthy endothelium to prevent hypercontraction of vascular smooth muscles, especially in patients with hyperglycemia. If endothelial vessels are damaged, however, it is crucial to manage hypercontraction of vascular smooth muscle in hyperglycemic conditions. The finding that Rb1 is effective as a preventive and therapeutic intervention for hyper-vasoconstriction induced by HG and ED in rat aorta provides a potential rationale for clinical trials aimed at evaluating the efficacy of Rb1 in patients with both hyperglycemia and ED.

4. Materials and Methods

4.1. Animals

Three-week-old male Sprague Dawley rats (weighing 65 ± 15 g) were purchased from Young Bio (Seongnam, Korea) and housed at a temperature of 21–23 °C and under a 12 h photoperiod. The rats were given free access to tap water and a standard chow diet comprised of 60% carbohydrate, 27% protein, and 13% fat (percentages of total kcal). After acclimatization, the rats were assigned to distinct groups (N = 4–11). The experimental protocol in this study was approved by the Institutional Committee for Animal Research Ethics of Korea University (KUIACUC-2021-0088).

4.2. Preparation of Aortic Rings

Rats were anesthetized with isoflurane, and their thoracic aortas were dissected. The aortic tissue was immersed in Krebs solution (118.3 mM NaCl, 25 mM NaHCO3, 1.22 mM KH2PO4, 11.1 mM glucose, 4.78 mM KCl, 1.2 mM MgCl2, 2.5 mM CaCl2) and the connective tissue was removed carefully. Each aorta was cut into rings 2–3 mm in length and placed in 37 °C chambers, which were continually aerated with a mixture of 5% CO2 and 95% O2. The aortic rings were connected to a DMT 620M (Danish Myo Technology, Aarhus, Denmark) with tungsten wires, and then stabilized at 1.0 g tension for 80 min. The aortic rings were pretreated with 10−4 M L-NAME to denudate the endothelium chemically and thus to assess only the vasoconstrictive responses of vascular smooth muscle. For the HG condition, the total glucose concentration in each chamber was adjusted to 25 mM [40] or 50 mM [41] for 30 min. Mannitol was used to prepare a high osmolarity control corresponding to HG50. The aortic rings were pretreated with 10−6 or 10−5 M Rb1 or Rg1, or with 10−5 M NAC, (an antioxidant) [42], and contraction was induced by adding 10−5 M PE. When the maximum vasoconstriction plateau was reached, 10−5 M acetylcholine was added to confirm endothelial denudation.

4.3. Involvement of K+ Channel in Vasoconstriction

To investigate whether the inhibitory effect of Rb1 on hyper-vasoconstriction under HG and ED conditions was associated with the activation of the K+ channel, the aortic rings were pretreated with K+ channel blockers. Briefly, the aortic rings with chemically denuded epithelium were treated with 10−3 M TEA to block the Ca2+-activated K+ channel (KCa2+), 10−6 M Gliben to block the KATP, 10−3 M BaCl2 to block the inward rectifier K+ channel (KIR), or 10−3 M 4-AP to block the voltage-dependent K+ channel (KV) [20]. The rings were subsequently treated with 10−5 M Rb1 prior to agonist-induced vasoconstriction.

4.4. Measurement of SR Ca2+ Release-Induced Vasoconstriction

To determine whether Rb1 was involved in PE-induced SR Ca2+ release, which causes the exposure of myosin-binding sites on actin and vascular smooth muscle contraction [35], the aortic rings were immersed in Ca2+-free Krebs solution supplemented with 10−4 M L-NAME, followed by the addition of 10−5 M PE to induce vasoconstriction due to SR Ca2+ release. The aortas were rinsed with Krebs solution three times to restore lost intracellular Ca2+, followed by rinsing with Ca2+-free Krebs solution two times. The rings were subsequently pretreated with 10−5 M Rb1 for 10 min, followed by the addition of 10−5 M PE. PE-induced vasoconstriction was calculated to estimate the amount of Ca2+ release from the SR [35].

4.5. Measurement of Extracellular Ca2+ Influx-Induced Vasoconstriction

Two types of Ca2+ channels, ROCC and VGCC, were selected to determine whether the effects of Rb1 included extracellular Ca2+ influx, thereby affecting vasoconstriction under HG and ED conditions. The aortic rings were immersed in Ca2+-free Krebs solution containing L-NAME, followed by the addition of 10−5 M PE (for Ca2+ influx via the ROCC) or 60 mM KCl (for Ca2+ influx via the VGCC) to induce vasoconstriction. The rings were subsequently treated with 10−6–10−2 M CaCl2 to obtain concentration–response curves. After rinsing with Ca2+-free Krebs solution, to evaluate the inhibitory effect of Rb1 on hyper-vasoconstriction induced by HG and ED via the ROCCs or VGCCs, the aortic rings were treated with 10−5 M Rb1 for 10 min prior to the addition of 10−5 M PE or 60 mM KCl and subsequent 10−6–10−2 M CaCl2. The percent PE- or KCl-induced vasoconstriction was calculated based on the maximal contractile response to 10−2 M CaCl2 [35].

4.6. Chemicals

All chemical reagents, including ACh, BaCl2, 4-AP, Gliben, glucose, L-NAME, mannitol, NAC, PE, Rb1 and Rg1, TEA, and dimethylsulfoxide (DMSO), were purchased from Sigma-Aldrich (St. Louis, MO, USA). Rb1, Rg1, and Gliben were dissolved in DMSO, whereas all other reagents were dissolved in distilled water.

4.7. Statistical Analysis

All data were expressed as mean ± SEM and analyzed using SPSS statistics version 26 software (IBM, IL, USA). The data for extracellular Ca2+ influx- and SR Ca2+ release-induced vasoconstriction were compared by paired t-tests. The other data were analyzed using one-way analysis of variance (ANOVA) followed by the least significant difference (LSD) test for post hoc comparison. p < 0.05 was deemed statistically significant.

5. Conclusions

In this study, we have demonstrated that Rb1 effectively reduced hyper-vasoconstriction induced by HG and ED (p = 0.004) via the inhibition of Ca2+ influx through the ROCC (10−6–10−4 M CaCl2, p < 0.001; 10−3–2.5 × 10−3 M CaCl2, p = 0.001) and the VGCC (10−6 M CaCl2, p = 0.003; 10−5–10−2 M CaCl2, p < 0.001) and partially through the activation of the KATP in rat aorta for the first time (Figure 3). Our research provides further evidence into clinical applicability that Rb1 could be recommended as a therapeutic agent for ED in diabetes and provides a guideline for clinical studies evaluating the importance of managing vascular function in patients with hyperglycemia and ED, including in patients with acute pancreatitis.

Author Contributions

Conceptualization, G.H.S.; methodology, G.H.S.; formal analysis, J.P., Y.K.S., U.K., and G.H.S.; investigation, J.P., Y.K.S., and U.K.; writing—original draft preparation, J.P., Y.K.S., and G.H.S.; writing—review and editing, G.H.S.; visualization, J.P., Y.K.S., and G.H.S.; supervision, G.H.S.; project administration, G.H.S.; funding acquisition, G.H.S. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2021R1A2C2004118) and the Institute of Nursing Research, Korea University Grant. This manuscript is a revision of J.P.’s master’s thesis from Korea University.

Institutional Review Board Statement

The animal study protocol was approved by the Institutional Animal Research and Ethics Committee of Korea University (KUIACUC-2021-0088).

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are available on request from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Richardson, A.; Park, W.G. Acute pancreatitis and diabetes mellitus: A review. Korean J. Intern. Med. 2021, 36, 15–24. [Google Scholar] [CrossRef] [PubMed]
  2. Dumnicka, P.; Maduzia, D.; Ceranowicz, P.; Olszanecki, R.; Drożdż, R.; Kuśnierz-Cabala, B. The interplay between inflammation, coagulation and endothelial injury in the early phase of acute pancreatitis: Clinical implications. Int. J. Mol. Sci. 2017, 18, 354. [Google Scholar] [CrossRef]
  3. Sinha, A.; Vyavahare, N.R. High-glucose levels and elastin degradation products accelerate osteogenesis in vascular smooth muscle cells. Diab. Vasc. Dis. Res. 2013, 10, 410–419. [Google Scholar] [CrossRef]
  4. Carrillo-Sepulveda, M.A.; Maddie, N.; Johnson, C.M.; Burke, C.; Lutz, O.; Yakoub, B.; Kramer, B.; Persand, D. Vascular hyperacetylation is associated with vascular smooth muscle dysfunction in a rat model of non-obese type 2 diabetes. Mol. Med. 2022, 28, 30. [Google Scholar] [CrossRef]
  5. Meza, C.A.; La Favor, J.D.; Kim, D.-H.; Hickner, R.C. Endothelial Dysfunction: Is There a Hyperglycemia-Induced Imbalance of NOX and NOS? Int. J. Mol. Sci. 2019, 20, 3775. [Google Scholar] [CrossRef]
  6. Mah, E.; Noh, S.K.; Ballard, K.D.; Matos, M.E.; Volek, J.S.; Bruno, R.S. Postprandial hyperglycemia impairs vascular endothelial function in healthy men by inducing lipid peroxidation and increasing asymmetric dimethylarginine: Arginine. J. Nutr. 2011, 141, 1961–1968. [Google Scholar] [CrossRef]
  7. Cai, X.; Zhang, Y.; Li, M.; Wu, J.H.; Mai, L.; Li, J.; Yang, Y.; Hu, Y.; Huang, Y. Association between prediabetes and risk of all cause mortality and cardiovascular disease: Updated meta-analysis. BMJ 2020, 370, m2297. [Google Scholar] [CrossRef]
  8. Zhang, X.; Liu, Z.; Zhong, C.; Pu, Y.; Yang, Z.; Bao, Y. Structure characteristics and immunomodulatory activities of a polysaccharide RGRP-1b from radix ginseng Rubra. Int. J. Biol. Macromol. 2021, 189, 980–992. [Google Scholar] [CrossRef]
  9. Lee, J.H.; Min, D.S.; Lee, C.W.; Song, K.H.; Kim, Y.S.; Kim, H.P. Ginsenosides from Korean Red Ginseng ameliorate lung inflammatory responses: Inhibition of the MAPKs/NF-κB/c-Fos pathways. J. Ginseng Res. 2018, 42, 476–484. [Google Scholar] [CrossRef]
  10. Lee, S.M.; Bae, B.S.; Park, H.W.; Ahn, N.G.; Cho, B.G.; Cho, Y.L.; Kwak, Y.S. Characterization of korean red ginseng (Panax ginseng Meyer): History, preparation method, and chemical composition. J. Ginseng Res. 2015, 39, 384–391. [Google Scholar] [CrossRef]
  11. Yu, S.; Zhou, X.; Li, F.; Xu, C.; Zheng, F.; Li, J.; Zhao, H.; Dai, Y.; Liu, S.; Feng, Y. Microbial transformation of ginsenoside Rb1, Re and Rg1 and its contribution to the improved anti-inflammatory activity of ginseng. Sci. Rep. 2017, 7, 138. [Google Scholar] [CrossRef]
  12. Cheng, Y.; Shen, L.-h.; Zhang, J.-t. Anti-amnestic and anti-aging effects of ginsenoside Rg1 and Rb1 and its mechanism of action. Acta Pharmacol. Sin. 2005, 26, 143–149. [Google Scholar] [CrossRef]
  13. Xu, M.; Ma, Q.; Fan, C.; Chen, X.; Zhang, H.; Tang, M. Ginsenosides Rb1 and Rg1 protect primary cultured astrocytes against oxygen-glucose deprivation/reoxygenation-induced injury via improving mitochondrial function. Int. J. Mol. Sci. 2019, 20, 6086. [Google Scholar] [CrossRef]
  14. Lin, Z.; Xie, R.; Zhong, C.; Huang, J.; Shi, P.; Yao, H. Recent progress (2015–2020) in the investigation of the pharmacological effects and mechanisms of ginsenoside Rb1, a main active ingredient in Panax ginseng Meyer. J. Ginseng Res. 2022, 46, 39–53. [Google Scholar] [CrossRef]
  15. Zhou, R.; He, D.; Zhang, H.; Xie, J.; Zhang, S.; Tian, X.; Zeng, H.; Qin, Y.; Huang, L. Ginsenoside Rb1 protects against diabetes-associated metabolic disorders in Kkay mice by reshaping gut microbiota and fecal metabolic profiles. J. Ethnopharmacol. 2023, 303, 115997. [Google Scholar] [CrossRef]
  16. Choi, K.T. Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C A Meyer. Acta Pharmacol. Sin. 2008, 29, 1109–1118. [Google Scholar] [CrossRef]
  17. Mohanan, P.; Subramaniyam, S.; Mathiyalagan, R.; Yang, D.C. Molecular signaling of ginsenosides Rb1, Rg1, and Rg3 and their mode of actions. J. Ginseng Res. 2018, 42, 123–132. [Google Scholar] [CrossRef]
  18. Zhou, P.; Zhang, X.; Guo, M.; Guo, R.; Wang, L.; Zhang, Z.; Lin, Z.; Dong, M.; Dai, H.; Ji, X.; et al. Ginsenoside Rb1 ameliorates CKD-associated vascular calcification by inhibiting the Wnt/β-catenin pathway. J. Cell. Mol. Med. 2019, 23, 7088–7098. [Google Scholar] [CrossRef]
  19. Wang, R.X.; He, R.L.; Jiao, H.X.; Dai, M.; Mu, Y.P.; Hu, Y.; Wu, Z.J.; Sham, J.S.K.; Lin, M.J. Ginsenoside Rb1 attenuates agonist-induced contractile response via inhibition of store-operated calcium entry in pulmonary arteries of normal and pulmonary hypertensive rats. Cell. Physiol. Biochem. 2015, 35, 1467–1481. [Google Scholar] [CrossRef]
  20. Wang, R.-X.; He, R.-L.; Jiao, H.-X.; Zhang, R.-T.; Guo, J.-Y.; Liu, X.-R.; Gui, L.-X.; Lin, M.-J.; Wu, Z.-J. Preventive treatment with ginsenoside Rb1 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats and involves store-operated calcium entry inhibition. Pharm. Biol. 2020, 58, 1055–1063. [Google Scholar] [CrossRef]
  21. Turpin, B.P.; Duckworth, W.C.; Solomon, S.S. Simulated hyperglycemic hyperosmolar syndrome. Impaired insulin and epinephrine effects upon lipolysis in the isolated rat fat cell. J. Clin. Investig. 1979, 63, 403–409. [Google Scholar] [CrossRef] [PubMed]
  22. Shor, D.; Harrison, S.; Anacker, K.; Wiley, J. Acute pancreatitis as a sequela of hypertriglyceridemia due to hyperosmolar hyperglycemic syndrome. Cureus 2021, 13, e19640. [Google Scholar] [CrossRef] [PubMed]
  23. Vanhoutte, P.M.; Shimokawa, H.; Feletou, M.; Tang, E.H.C. Endothelial dysfunction and vascular disease—A 30th anniversary update. Acta Physiol. 2017, 219, 22–96. [Google Scholar] [CrossRef]
  24. Xu, J.; Yang, H.; Yang, L.; Wang, Z.; Qin, X.; Zhou, J.; Dong, L.; Li, J.; Zhu, M.; Zhang, X.; et al. Acute glucose influx-induced mitochondrial hyperpolarization inactivates myosin phosphatase as a novel mechanism of vascular smooth muscle contraction. Cell Death Dis. 2021, 12, 176. [Google Scholar] [CrossRef]
  25. Han, A.Y.; Ha, S.M.; Shin, Y.K.; Seol, G.H. Ginsenoside Rg-1 prevents elevated cytosolic Ca2+ via store-operated Ca2+ entry in high-glucose–stimulated vascular endothelial and smooth muscle cells. BMC Complement. Med. Ther. 2022, 22, 166. [Google Scholar] [CrossRef]
  26. Lu, Y.; Zhang, Q.; Lou, J. Blood glucose-related indicators are associated with in-hospital mortality in critically ill patients with acute pancreatitis. Sci. Rep. 2021, 11, 15351. [Google Scholar] [CrossRef]
  27. Zhang, X.-J.; He, C.; Tian, K.; Li, P.; Su, H.; Wan, J.-B. Ginsenoside Rb1 attenuates angiotensin II-induced abdominal aortic aneurysm through inactivation of the JNK and p38 signaling pathways. Vascul. Pharmacol. 2015, 73, 86–95. [Google Scholar] [CrossRef]
  28. Wang, N.; Wan, J.-B.; Chan, S.-W.; Deng, Y.-H.; Yu, N.; Zhang, Q.-W.; Wang, Y.-T.; Lee, S.M.-Y. Comparative study on saponin fractions from Panax notoginseng inhibiting inflammation-induced endothelial adhesion molecule expression and monocyte adhesion. Chin. Med. 2011, 6, 37. [Google Scholar] [CrossRef]
  29. Kinoshita, H.; Azma, T.; Nakahata, K.; Iranami, H.; Kimoto, Y.; Dojo, M.; Yuge, O.; Hatano, Y. Inhibitory effect of high concentration of glucose on relaxations to activation of ATP-sensitive K+ channels in human omental artery. Arter. Thromb Vasc. Biol. 2004, 24, 2290–2295. [Google Scholar] [CrossRef]
  30. Flechtner, I.; De Lonlay, P.; Polak, M. Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: Therapeutic consequences. Diabetes Metab. 2006, 32, 569–580. [Google Scholar] [CrossRef]
  31. Aguilar-Bryan, L.; John, P.; Clement, I.; Gonzalez, G.; Kunjilwar, K.; Babenko, A.; Bryan, J. Toward understanding the assembly and structure of KATP channels. Physiol. Rev. 1998, 78, 227–245. [Google Scholar] [CrossRef] [PubMed]
  32. Zhou, W.J.; Li, J.L.; Zhou, Q.M.; Cai, F.F.; Chen, X.L.; Lu, Y.Y.; Zhao, M.; Su, S.B. Ginsenoside Rb1 pretreatment attenuates myocardial ischemia by reducing calcium/calmodulin-dependent protein kinase II-medicated calcium release. World J. Trad. Chin. Med. 2020, 6, 284–294. [Google Scholar] [CrossRef]
  33. Lin, Z.Y.; Chen, L.M.; Zhang, J.; Pan, X.D.; Zhu, Y.G.; Ye, Q.Y.; Huang, H.P.; Chen, X.C. Ginsenoside Rb1 selectively inhibits the activity of L-type voltage-gated calcium channels in cultured rat hippocampal neurons. Acta Pharmacol. Sin. 2012, 33, 438–444. [Google Scholar] [CrossRef] [PubMed]
  34. Sabatini, P.V.; Speckmann, T.; Lynn, F.C. Friend and foe: β-cell Ca2+ signaling and the development of diabetes. Mol. Metab. 2019, 21, 1–12. [Google Scholar] [CrossRef]
  35. Yang, S.; Xu, Z.Y.; Lin, C.C.; Li, H.; Sun, J.H.; Chen, J.G.; Wang, C.M. Schisantherin A causes endothelium-dependent and -independent vasorelaxation in isolated rat thoracic aorta. Life Sci. 2020, 245, 117357. [Google Scholar] [CrossRef]
  36. Peng, H.; Xing, Y.F.; Ye, Z.C.; Li, C.M.; Luo, P.L.; Li, M.; Lou, T.Q. High glucose induces activation of the local renin-angiotensin system in glomerular endothelial cells. Mol. Med. Rep. 2014, 9, 450–456. [Google Scholar] [CrossRef]
  37. Cosentino, F.; Eto, M.; Paolis, P.D.; Loo, B.v.d.; Bachschmid, M.; Ullrich, V.; Kouroedov, A.; Gatti, C.D.; Joch, H.; Volpe, M.; et al. High Glucose Causes Upregulation of Cyclooxygenase-2 and Alters Prostanoid Profile in Human Endothelial Cells. Circulation 2003, 107, 1017–1023. [Google Scholar] [CrossRef]
  38. Padilla, J.; Carpenter, A.J.; Das, N.A.; Kandikattu, H.K.; López-Ongil, S.; Martinez-Lemus, L.A.; Siebenlist, U.; DeMarco, V.G.; Chandrasekar, B. TRAF3IP2 mediates high glucose-induced endothelin-1 production as well as endothelin-1-induced inflammation in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2018, 314, H52–H64. [Google Scholar] [CrossRef]
  39. Zhou, P.; Xie, W.; He, S.; Sun, Y.; Meng, X.; Sun, G.; Sun, X. Ginsenoside Rb1 as an Anti-Diabetic Agent and Its Underlying Mechanism Analysis. Cells 2019, 8, 204. [Google Scholar] [CrossRef]
  40. Zhuang, Y.; Chan, D.K.; Haugrud, A.B.; Miskimins, W.K. Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo. PLoS ONE 2014, 9, e108444. [Google Scholar] [CrossRef]
  41. Wong, N.L.; Achike, F.I. Gender discrimination in the influence of hyperglycemia and hyperosmolarity on rat aortic tissue responses to insulin. Regul. Pept. 2010, 163, 113–119. [Google Scholar] [CrossRef] [PubMed]
  42. Hsu, S.-S.; Lin, Y.-S.; Chio, L.-M.; Liang, W.-Z. Evaluation of the mycotoxin patulin on cytotoxicity and oxidative stress in human glioblastoma cells and investigation of protective effect of the antioxidant N-acetylcysteine (NAC). Toxicon 2023, 221, 106957. [Google Scholar] [CrossRef] [PubMed]
Pharmaceuticals 16 01238 g001
Figure 1. Effect of Rb1 on vasoconstriction induced by HG and ED. (A) PE (10−5 M)-induced vasoconstriction in the presence of HG. (B) Effects of ginsenoside Rb1 (10−6 and 10−5 M) and Rg1 (10−5 M) on vascular smooth muscle constriction. Results are presented as the mean ± SEM. Data were analyzed by one-way ANOVA followed by the LSD test for post hoc analysis (n = 12–18; ++ p < 0.01 vs. Control; # p < 0.05 vs. L-NAME; ## p < 0.01 vs. L-NAME; * p < 0.05 vs. L-NAME + HG50; ** p < 0.01 vs. L-NAME + HG50). Abbreviations: ACh, acetylcholine; ED, endothelial dysfunction; HG, high glucose; L-NAME, Nω-Nitro-L-arginine methyl ester hydrochloride; -EC, endothelium-denuded; NAC, N-acetylcysteine; PE, phenylephrine; Rb1, ginsenoside Rb1; Rg1, ginsenoside Rg1.
Figure 1. Effect of Rb1 on vasoconstriction induced by HG and ED. (A) PE (10−5 M)-induced vasoconstriction in the presence of HG. (B) Effects of ginsenoside Rb1 (10−6 and 10−5 M) and Rg1 (10−5 M) on vascular smooth muscle constriction. Results are presented as the mean ± SEM. Data were analyzed by one-way ANOVA followed by the LSD test for post hoc analysis (n = 12–18; ++ p < 0.01 vs. Control; # p < 0.05 vs. L-NAME; ## p < 0.01 vs. L-NAME; * p < 0.05 vs. L-NAME + HG50; ** p < 0.01 vs. L-NAME + HG50). Abbreviations: ACh, acetylcholine; ED, endothelial dysfunction; HG, high glucose; L-NAME, Nω-Nitro-L-arginine methyl ester hydrochloride; -EC, endothelium-denuded; NAC, N-acetylcysteine; PE, phenylephrine; Rb1, ginsenoside Rb1; Rg1, ginsenoside Rg1.
Pharmaceuticals 16 01238 g001
Pharmaceuticals 16 01238 g002
Figure 2. Mechanisms underlying the action of Rb1 on hyper-vasoconstriction induced by HG and ED. (A) Effect of Rb1 (10−5 M) on PE (10−5 M)-induced vasoconstriction through the K+ channel. (B) Effect of Rb1 (10−5 M) on SR Ca2+ release-induced vasoconstriction. (C,D) Effects of Rb1 (10−5 M) on extracellular Ca2+ influx (10−6–10−2 M CaCl2)-induced vasoconstriction via (C) ROCC and (D) VGCC. All results are presented as the mean ± SEM. Extracellular Ca2+ influx and SR Ca2+ release were compared by paired t-tests (n = 12–16; ** p < 0.01 vs. L-NAME + HG50; *** p < 0.001 vs. L-NAME + HG50). All other parameters were compared by one-way ANOVA followed by LSD tests (n = 11–18). Abbreviations: BaCl2, barium chloride; ED, endothelial dysfunction; 4-AP, 4-aminopyridine; Gliben, glibenclamide; HG, high glucose; L-NAME, NG-nitro-L-arginine methyl ester; -EC, endothelium-denuded; PE, phenylephrine; Rb1, ginsenoside Rb1; ROCC, receptor-operated calcium channel; SR, sarcoplasmic reticulum; TEA, tetraethylamine; VGCC, voltage-gated calcium channel.
Figure 2. Mechanisms underlying the action of Rb1 on hyper-vasoconstriction induced by HG and ED. (A) Effect of Rb1 (10−5 M) on PE (10−5 M)-induced vasoconstriction through the K+ channel. (B) Effect of Rb1 (10−5 M) on SR Ca2+ release-induced vasoconstriction. (C,D) Effects of Rb1 (10−5 M) on extracellular Ca2+ influx (10−6–10−2 M CaCl2)-induced vasoconstriction via (C) ROCC and (D) VGCC. All results are presented as the mean ± SEM. Extracellular Ca2+ influx and SR Ca2+ release were compared by paired t-tests (n = 12–16; ** p < 0.01 vs. L-NAME + HG50; *** p < 0.001 vs. L-NAME + HG50). All other parameters were compared by one-way ANOVA followed by LSD tests (n = 11–18). Abbreviations: BaCl2, barium chloride; ED, endothelial dysfunction; 4-AP, 4-aminopyridine; Gliben, glibenclamide; HG, high glucose; L-NAME, NG-nitro-L-arginine methyl ester; -EC, endothelium-denuded; PE, phenylephrine; Rb1, ginsenoside Rb1; ROCC, receptor-operated calcium channel; SR, sarcoplasmic reticulum; TEA, tetraethylamine; VGCC, voltage-gated calcium channel.
Pharmaceuticals 16 01238 g002
Pharmaceuticals 16 01238 g003
Figure 3. Proposed mechanisms of action of Rb1 in reducing hyper-vasoconstriction induced by high glucose and endothelial dysfunction in rat aorta. Abbreviations: IP3R, inositol 1,4,5-trisphosphate receptor; KATP, ATP-sensitive K+ channel; KCa2+, Ca2+-activated K+ channel; KIR, inward rectifier K+ channel; KV, voltage-dependent K+ channel; Rb1, ginsenoside Rb1; ROCC, receptor-operated calcium channel; SR, sarcoplasmic reticulum; VGCC, voltage-gated calcium channel.
Figure 3. Proposed mechanisms of action of Rb1 in reducing hyper-vasoconstriction induced by high glucose and endothelial dysfunction in rat aorta. Abbreviations: IP3R, inositol 1,4,5-trisphosphate receptor; KATP, ATP-sensitive K+ channel; KCa2+, Ca2+-activated K+ channel; KIR, inward rectifier K+ channel; KV, voltage-dependent K+ channel; Rb1, ginsenoside Rb1; ROCC, receptor-operated calcium channel; SR, sarcoplasmic reticulum; VGCC, voltage-gated calcium channel.
Pharmaceuticals 16 01238 g003
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Park, J.; Shin, Y.K.; Kim, U.; Seol, G.H. Ginsenoside Rb1 Reduces Hyper-Vasoconstriction Induced by High Glucose and Endothelial Dysfunction in Rat Aorta. Pharmaceuticals 2023, 16, 1238. https://doi.org/10.3390/ph16091238

AMA Style

Park J, Shin YK, Kim U, Seol GH. Ginsenoside Rb1 Reduces Hyper-Vasoconstriction Induced by High Glucose and Endothelial Dysfunction in Rat Aorta. Pharmaceuticals. 2023; 16(9):1238. https://doi.org/10.3390/ph16091238

Chicago/Turabian Style

Park, Jubin, You Kyoung Shin, Uihwan Kim, and Geun Hee Seol. 2023. "Ginsenoside Rb1 Reduces Hyper-Vasoconstriction Induced by High Glucose and Endothelial Dysfunction in Rat Aorta" Pharmaceuticals 16, no. 9: 1238. https://doi.org/10.3390/ph16091238

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop